Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
Evaluation of waning of SARS-CoV-2 vaccine–induced immunity: a systematic review and meta-analysis
Importance Estimates of the rate of waning of vaccine effectiveness (VE) against COVID-19
are key to assess population levels of protection and future needs for booster doses to face …
are key to assess population levels of protection and future needs for booster doses to face …
A bivalent omicron-containing booster vaccine against Covid-19
S Chalkias, C Harper, K Vrbicky… - … England Journal of …, 2022 - Mass Medical Soc
Background The safety and immunogenicity of the bivalent omicron-containing mRNA-
1273.214 booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …
1273.214 booster vaccine are not known. Methods In this ongoing, phase 2–3 study, we …
Immune boosting by B. 1.1. 529 (Omicron) depends on previous SARS-CoV-2 exposure
The Omicron, or Pango lineage B. 1.1. 529, variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …
coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and …
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective …
AS Lauring, MW Tenforde, JD Chappell, M Gaglani… - bmj, 2022 - bmj.com
Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta,
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA. 5 Omicron variant in mice
SM Scheaffer, D Lee, B Whitener, B Ying, K Wu… - Nature medicine, 2023 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1. 529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in Southern California
Epidemiologic surveillance has revealed decoupling of Coronavirus Disease 2019 (COVID-
19) hospitalizations and deaths from case counts after emergence of the Omicron (B. 1.1 …
19) hospitalizations and deaths from case counts after emergence of the Omicron (B. 1.1 …
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar
Abstract SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants are genetically divergent. We
conducted a matched, test-negative, case-control study to estimate duration of protection of …
conducted a matched, test-negative, case-control study to estimate duration of protection of …